comparemela.com

Latest Breaking News On - France french national institute of health - Page 4 : comparemela.com

Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China

Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

QUANTUM GENOMICS: Orient EuroPharma Acquires Equity Stake in Quantum Genomics

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs that directly targets the brain to treat difficult- to-treat/resistant

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

Share: PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure today announced the launch of its Phase III REFRESH study in difficult-to-treat ( (2) hypertension. This new study is part of firibastat s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients. We are thrilled to launch this new pivotal study as a precursor to potential market approval of single dose firibastat, which we believe to be the best regimen for chronic treatment of resistant of difficult-to-treat hypertension, said Jean-Philippe Milon, Chief Executive Officer at Quantum Genomics.

Quantum Genomics Signs a Strategic Contract with Delpharm

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Quantum Genomics Signs a Strategic Contract with Delpharm Quantum GenomicsDecember 16, 2020 GMT PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant hypertension and heart failure, announces today that it has signed a strategic contract with Delpharm for the manufacture of the next clinical batches of firibastat tablets on an industrial scale and the establishment of production lines for future commercial batches.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.